<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145596</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-105</org_study_id>
    <nct_id>NCT04145596</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment</brief_title>
  <official_title>A Phase 1 Study to Investigate a Single Bolus Dose Followed With a 30 Minute Constant Infusion of HSK3486 on the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment (Single-Center, Open-label, Parallel-Group)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sichuan Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the pharmacokinetics/Pharmacodynamics of the HSK3486 in Patients With Mild and
      Moderate Hepatic Impairment Compared with Healthy Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, non-randomized, parallel-controlled Phase I clinical
      study carried out in patients with compensated chronic liver disease (Child-Pugh A), patients
      with decompensated chronic liver disease (Child-Pugh B), and age-, weight-, and
      gender-matched subjects with normal liver functions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak concentration (Cmax)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>Cmax（a measure of the body's exposure to HSK3486）will be compared between normal hepatic function patients and Patients with Compensated Chronic Liver Disease (Child-Pugh A) or Patients with Decompensated Chronic Liver Disease (Child-Pugh B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>AUC（a measure of the body's exposure to HSK3486）will be compared between normal hepatic function patients and Patients with Compensated Chronic Liver Disease (Child-Pugh A) or Patients with Decompensated Chronic Liver Disease (Child-Pugh B).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MOAA/S(modified observer's assessment of alert /sedation)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index(BIS)</measure>
    <time_frame>-5 minutes before administration until 1 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
    <description>time to peak observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>-30 minutes before administration until 24 hours post administration on day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure（systolic, diastolic and mean arterial pressure）</measure>
    <time_frame>from the screening to 3 days post-dose</time_frame>
    <description>safety endpoits</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Compensated Chronic Liver Disease (Child-Pugh A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Decompensated Chronic Liver Disease (Child-Pugh B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers（Normal liver functions）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.</description>
    <arm_group_label>Compensated Chronic Liver Disease (Child-Pugh A)</arm_group_label>
    <arm_group_label>Decompensated Chronic Liver Disease (Child-Pugh B)</arm_group_label>
    <arm_group_label>healthy volunteers（Normal liver functions）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Sign the informed consent form and fully understand the content, procedure and
             possible adverse effects before the trial starts；

          2. Able to complete the study in compliance with the requirements of the clinical trial
             protocol;

          3. Subjects (including their partners) are willing to voluntarily adopt an effective
             measure of contraception starting from screening to 6 months after the last dose of
             the investigational drug.

          4. Male or female subjects aged 18-64 years old (including 18 and 64 years old);

          5. Male subjects weighing ≥ 50 kg, female subjects weighing ≥ 45 kg;Body mass index (BMI)
             = weight (kg)/height2 (m2); BMI of ≥ 18 and ≤ 30 kg/m2 (inclusive);

          6. Blood pressure between 90-149/60-94 mmHg (inclusive); heart rate between 55-100 bpm
             (inclusive); body temperature between 35.9-37.6°C (inclusive); respiratory rate
             between 12-20 breaths per min (inclusive); SpO2 when inhaling ≥ 95%;

          7. Normal physical examination results or abnormal physical examination results with no
             clinical significance;

          8. For subjects with normal liver functions, their clinical laboratory tests (blood
             routine, blood biochemistry, urine routine, and coagulation function) should be normal
             or abnormal without clinical significance;

          9. No potential difficult airway (modified Mallampati score of Grade I to II);

         10. For subjects with normal liver functions, they should have no history of primary
             diseases in major organs, including but not limited to gastrointestinal, respiratory,
             renal, hepatic, neurological, hematological, , endocrine, oncological, immunological,
             psychiatric or cardiovascular and cerebrovascular diseases;

             Patients with Hepatic Insufficiency Must Also Meet the Following Inclusion Criteria:

         11. Child-Pugh grade A or B hepatic insufficiency caused by previous primary liver
             diseases: including non-alcoholic steatohepatitis and viral hepatitis (hepatitis B,
             hepatitis C);

         12. The liver function is determined by the investigators as stable within 14 days before
             drug administration;

         13. Have not used any drug or dosing regimen within 4 weeks before screening that can
             stabilize the primary liver disease.

        Exclusion Criteria:

          1. Have not used any drug or dosing regimen within 4 weeks before screening that can
             stabilize the primary liver disease;

          2. Patient having contraindications to deep sedation/general anesthesia or a history of
             past sedation/anesthesia accidents;

          3. Known sensitivity to excipients in HSK3486 injectable emulsion (soybean oil, glycerin,
             triglyceride, egg lecithin, sodium oleate and sodium hydroxide); or with allergic
             constitution (including history of drug allergies and allergic diseases);

          4. History of alcohol abuse (&gt; 2 units of alcohol consumed per day: 1 unit = 285 mL of
             beer, or 25 mL of liquor, or 100 mL of wine) within 3 months prior to screening;

          5. History of drug abuse within 3 months prior to screening, or a history of long-term
             use of benzodiazepines;

          6. Blood/plasma donation or blood loss of ≥ 200 mL, or plasma exchange within 30 days
             prior to screening;

          7. In receipt of prescription drugs, Chinese herbal medicines, over-the-counter drugs or
             food supplements (such as vitamins and calcium supplements) other than contraceptives,
             paracetamol, non-steroidal anti-inflammatory drugs, topical over-the-counter
             preparations, within 2 weeks prior to screening (patients with hepatic insufficiency
             can also use drugs for treating primary liver diseases);

          8. Participated in other drug/medical device trials within 3 month prior to screening;

          9. Patients with clinically significant abnormalities in ECG (such as
             tachycardia/bradycardia requiring medication, II-III degree atrioventricular block or
             QTcF interval ≥ 450 ms (Fridericia's correction formula), or other clinically
             significant abnormalities determined by the clinician);

         10. Female subjects in lactation or having positive serum pregnancy test results during
             the screening period or the trial;

         11. Positive screening result of any indicators of hepatitis B surface antigen, hepatitis
             C antibody or hepatitis C core antigen, HIV antibody, or syphilis antibody (hepatitis
             B surface antigen, hepatitis C antibody or hepatitis C core antigen may be positive
             for patients with hepatic insufficiency);

         12. Subjects with serious or clinically significant infections (such as infections of the
             respiratory tract or central nervous system), trauma, or major surgery within 4 weeks
             prior to screening;

         13. Subjects expected to have surgery or hospitalization during the trial;

         14. Subjects who have consumed any beverages or foods containing alcohol (or positive
             alcohol breath test results), grapefruit juice or methylxanthine (such as coffee, tea,
             cola, chocolate, and functional drinks), participated in strenuous physical
             activities, and with other factors that may affect drug absorption, distribution,
             metabolism, and excretion within 1 day prior to dose administration;

         15. Subjects with positive urine drug screening results (morphine, methamphetamine,
             ketamine, marijuana, ecstasy pills);

         16. Subjects unsuitable for arterial blood collection, such as subjects who have positive
             Allen's test results;

         17. Subjects who are unable to fast for 8 hrs before dose administration;

         18. Subjects who have used propofol, other sedatives/anesthetics, and/or opioid analgesics
             or compounds containing analgesics within 72 hrs prior to dose administration;

         19. Subjects judged by the investigator to be unsuitable for participating in this trial
             for any reason.

             The Following Exclusion Criteria are Added for Patients with Hepatic Insufficiency:

         20. Clinical laboratory abnormalities with clinical significance, or other clinical
             findings showing the following illnesses with clinically significance, including but
             not limited to gastrointestinal, respiratory, renal, neural, hematological, endocrine,
             neoplastic, immunological, psychiatric or cardiovascular and cerebrovascular diseases
             other than primary liver diseases;

         21. Patients with liver failure, or with cirrhotic combined with hepatic encephalopathy,
             hepatocellular carcinoma, and esophageal and gastric variceal bleeding and other
             complications considered by the investigator as unsuitable for the clinical study;

         22. History of liver transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-hua Ding, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Phase I Clinical Trial Laboratory，The First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shi-ping Ma, PhD</last_name>
    <phone>(021)50799069</phone>
    <email>masp@haisco.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kai Chen, PhD</last_name>
    <phone>(028)67258864</phone>
    <email>chenk@haisco.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phase I Clinical Trial Laboratory, The First Hospital of Jilin University</name>
      <address>
        <city>Chang chun</city>
        <state>Ji Lin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhua Ding, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00254</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Qin L, Ren L, Wan S, Liu G, Luo X, Liu Z, Li F, Yu Y, Liu J, Wei Y. Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics. J Med Chem. 2017 May 11;60(9):3606-3617. doi: 10.1021/acs.jmedchem.7b00254. Epub 2017 Apr 28.</citation>
    <PMID>28430430</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

